Pfizer Acquires Stake in Redvax
Pfizer Inc. has acquired a controlling interest in Redvax GmbH, a spin-off from Redbiotec AG, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. This transaction provides access to a preclinical human cytomegalovirus (CMV) vaccine candidate as well as intellectual property and a technology platform related to a second, undisclosed vaccine program.
CMV is a herpes virus, infecting 50-90% of the adult population, with a majority remaining asymptomatic. A large segment of young adults, especially women of childbearing age who remain CMV negative, are at high risk of CMV infection during pregnancy and of passing the infection on to the unborn child (congenital infection). One out of every five children born with CMV infection may experience hearing loss and severe neurologic disorders.